Dataset Open Access

Expression and purification of HTT79-3144 with and without HAP40 from Sf9 Insect cells - 2019/01/28

Harding, Rachel; Hutchinson, Ashley; Seitova, Alma; Arrowsmith, Cheryl; Lee, Matt


Dublin Core Export

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Harding, Rachel</dc:creator>
  <dc:creator>Hutchinson, Ashley</dc:creator>
  <dc:creator>Seitova, Alma</dc:creator>
  <dc:creator>Arrowsmith, Cheryl</dc:creator>
  <dc:creator>Lee, Matt</dc:creator>
  <dc:date>2019-01-28</dc:date>
  <dc:description>Project: Biophysical investigation of purified HTT protein samples

Experiment: Expression and purification of HTT79-3144 with and without HAP40 from Sf9 Insect cells

Date completed:­ 2019/01/28

Rationale: HTT lacking the unstructured region of exon1 (aa. 1-78 which are not resolved in the cryoEM model PDB ID 6EZ8) may serve as a useful control when determining exon1-dependent functionality of the HTT protein. Apo and HAP40-bound HTT79-3144 will be produced from Sf9 insect cell expression system. </dc:description>
  <dc:description>Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.</dc:description>
  <dc:identifier>https://zenodo.org/record/2598804</dc:identifier>
  <dc:identifier>10.5281/zenodo.2598804</dc:identifier>
  <dc:identifier>oai:zenodo.org:2598804</dc:identifier>
  <dc:relation>doi:10.5281/zenodo.2598803</dc:relation>
  <dc:relation>url:https://zenodo.org/communities/labscribbles</dc:relation>
  <dc:relation>url:https://zenodo.org/communities/openlabnotebooks</dc:relation>
  <dc:relation>url:https://zenodo.org/communities/sgc-opennotebook</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>https://creativecommons.org/licenses/by/4.0/legalcode</dc:rights>
  <dc:subject>Huntingtin</dc:subject>
  <dc:subject>Protein production</dc:subject>
  <dc:subject>Huntington's disease</dc:subject>
  <dc:subject>BVES production</dc:subject>
  <dc:title>Expression and purification of HTT79-3144 with and without HAP40 from Sf9 Insect cells - 2019/01/28</dc:title>
  <dc:type>info:eu-repo/semantics/other</dc:type>
  <dc:type>dataset</dc:type>
</oai_dc:dc>
87
49
views
downloads
All versions This version
Views 8788
Downloads 4949
Data volume 22.7 MB22.7 MB
Unique views 7677
Unique downloads 3535

Share

Cite as